A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

Completed · Phase 3 · Has a placebo group

Conditions studied: Transient Insomnia

In brief

The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.

Key facts

Study ID

NCT00667108

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

784

Starts

2004-10-01

Expected to finish

2005-01-01

Last updated by the study team

2021-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged >/= 18 years
• Females of child-bearing potential using medically-acceptable method of birth control >/= 1 month prior to screening

You may not qualify if…

• Current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition)
• Recreational drug use within past 30 days

Where it is running

• Pfizer Investigational Site — Anaheim, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Orlando, Florida, United States
• Pfizer Investigational Site — Boise, Idaho, United States
• Pfizer Investigational Site — Mount Laurel, New Jersey, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Spartanburg, South Carolina, United States
• Pfizer Investigational Site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.